Sei Investments Co. Buys 83,040 Shares of Personalis, Inc. $PSNL

Sei Investments Co. raised its position in shares of Personalis, Inc. (NASDAQ:PSNL) by 148.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 139,046 shares of the company’s stock after purchasing an additional 83,040 shares during the period. Sei Investments Co. owned 0.13% of Personalis worth $886,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of PSNL. Royal Bank of Canada lifted its position in shares of Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after buying an additional 2,395 shares during the last quarter. Dynamic Technology Lab Private Ltd increased its holdings in Personalis by 75.6% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after acquiring an additional 33,044 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Personalis by 55.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock valued at $998,000 after acquiring an additional 101,706 shares during the period. Focus Partners Wealth purchased a new stake in Personalis during the first quarter valued at about $47,000. Finally, JPMorgan Chase & Co. lifted its holdings in Personalis by 505.6% during the second quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock valued at $193,000 after purchasing an additional 24,621 shares during the last quarter. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Stock Performance

Personalis stock opened at $14.42 on Friday. The stock has a market cap of $1.51 billion, a P/E ratio of -13.23 and a beta of 2.27. Personalis, Inc. has a fifty-two week low of $4.44 and a fifty-two week high of $16.39. The firm’s fifty day moving average price is $12.62 and its 200-day moving average price is $9.45.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The business had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. Sell-side analysts predict that Personalis, Inc. will post -1.07 earnings per share for the current year.

Insider Activity

In other news, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the completion of the sale, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,558,668.88. This trade represents a 29.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of Personalis stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $14.00, for a total value of $69,748.00. Following the sale, the chief financial officer owned 198,833 shares of the company’s stock, valued at approximately $2,783,662. This trade represents a 2.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 435,032 shares of company stock worth $5,599,929. Insiders own 4.20% of the company’s stock.

Analyst Upgrades and Downgrades

PSNL has been the subject of several recent research reports. Lake Street Capital downgraded shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a research note on Monday, July 20th. Needham & Company LLC downgraded shares of Personalis from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Zacks Research lowered shares of Personalis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 21st. TD Cowen reissued a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Finally, Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Personalis currently has a consensus rating of “Hold” and an average target price of $14.25.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.